PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA.
Latest Information Update: 04 Feb 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Cholangiocarcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms SORACCC
Most Recent Events
- 31 May 2011 New trial record